Koneksa, the leader in designing and validating digital biomarkers to accelerate drug development, announced today the completion of a $45M Series C financing round, led by AyurMaya, an affiliated fund of Matrix Capital Management, with participation from Takeda Ventures and Velosity Capital.

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical measures. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize treatment effect detection in clinical research. Learn more at koneksahealth.com.

Koneksa Raises $45M Series C Financing To Accelerate Expansion Of Digital Biomarker Platform

Description

Company Information

Funding Insights

Koneksa Raises $45M Series C Financing To Accelerate Expansion Of Digital Biomarker Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information